Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2023
Context: The filing addresses a specific inquiry regarding the company's banking relationships in the wake of the Silicon Valley Bank (SVB) crisis.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a regulatory disclosure regarding banking exposure rather than a financial results report.
Material Changes
No material changes to financial operations or business strategy are reported in this document. The sole material disclosure is the confirmation of the company's lack of exposure to Silicon Valley Bank.
Management Commentary and Risks
Regulation FD Disclosure (Item 7.01): Management confirms that Aquestive Therapeutics, Inc. does not hold any deposits, securities, or maintain any accounts at Silicon Valley Bank. This disclosure was made to clarify the company's liquidity position and risk exposure regarding the SVB situation.
Legal Disclaimer: The company notes that this information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not intended to constitute a determination of materiality under Regulation FD.
Investor Verification Checklist
- Verify the company's current cash and cash equivalents location by reviewing the most recent 10-Q or 10-K filing.
- Confirm the company's total cash balance to assess overall liquidity independent of this specific SVB disclosure.
- Review subsequent filings for any updates on banking relationships or liquidity constraints.